Synairgen Yönetim

Yönetim kriter kontrolleri 4/4

Synairgen CEO'su Richard Marsden, Sep2009 tarihinde atandı, in görev süresi 14.75 yıldır. in toplam yıllık tazminatı £ 328.00K olup, şirket hissesi ve opsiyonları dahil olmak üzere 94.5% maaş ve 5.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.49% ine doğrudan sahiptir ve bu hisseler € 49.35K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.4 yıl ve 16.5 yıldır.

Anahtar bilgiler

Richard Marsden

İcra Kurulu Başkanı

UK£328.0k

Toplam tazminat

CEO maaş yüzdesi	94.5%
CEO görev süresi	14.8yrs
CEO sahipliği	0.5%
Yönetim ortalama görev süresi	3.4yrs
Yönetim Kurulu ortalama görev süresi	16.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Richard Marsden'un ücretlendirmesi Synairgen'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2023	UK£328k	UK£310k	-UK£8m
Sep 30 2023	n/a	n/a	-UK£9m
Jun 30 2023	n/a	n/a	-UK£10m
Mar 31 2023	n/a	n/a	-UK£14m
Dec 31 2022	UK£328k	UK£310k	-UK£18m
Sep 30 2022	n/a	n/a	-UK£23m
Jun 30 2022	n/a	n/a	-UK£28m
Mar 31 2022	n/a	n/a	-UK£38m
Dec 31 2021	UK£1m	UK£256k	-UK£49m
Sep 30 2021	n/a	n/a	-UK£46m
Jun 30 2021	n/a	n/a	-UK£43m
Mar 31 2021	n/a	n/a	-UK£28m
Dec 31 2020	UK£415k	UK£194k	-UK£14m
Sep 30 2020	n/a	n/a	-UK£10m
Jun 30 2020	n/a	n/a	-UK£6m
Mar 31 2020	n/a	n/a	-UK£5m
Dec 31 2019	UK£289k	UK£190k	-UK£4m
Sep 30 2019	n/a	n/a	-UK£4m
Jun 30 2019	n/a	n/a	-UK£4m
Mar 31 2019	n/a	n/a	-UK£3m
Dec 31 2018	UK£205k	UK£186k	-UK£3m
Sep 30 2018	n/a	n/a	-UK£898k
Jun 30 2018	n/a	n/a	UK£2m
Mar 31 2018	n/a	n/a	UK£2m
Dec 31 2017	UK£336k	UK£182k	UK£2m

Tazminat ve Piyasa: Richard 'ın toplam tazminatı ($USD 414.63K ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 474.54K ).

Tazminat ve Kazançlar: Richard 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Richard Marsden (57 yo)

14.8yrs

Görev süresi

UK£328,000

Tazminat

Mr. Richard Marsden has been Chief Executive Officer of Synairgen Research Ltd since September 2009. Mr. Marsden has been Managing Director and Executive Director at Synairgen since June 2004 has been its...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Richard Marsden	CEO, MD & Executive Director	14.8yrs	UK£328.00k	0.49% € 49.4k
Stephen Holgate	Co-Founder	no data	UK£40.00k	0.45% € 45.2k
Joseph Colliver	CFO & Executive Director	less than a year	UK£197.41k	Veri yok
Phillip Monk	Chairman of Scientific Advisory Board	14.8yrs	UK£241.00k	0.21% € 21.0k
Donna Davies	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Ratko Djukanovic	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Gareth Walters	Chief Regulatory Officer	2.7yrs	Veri yok	Veri yok
Jody Brookes	Senior VP & Head of Clinical Operations	12.5yrs	Veri yok	Veri yok
Richard Francis	Senior VP and Head of CMC & Quality	2.8yrs	Veri yok	Veri yok
Victoria Tear	Head of Laboratory	5.2yrs	Veri yok	Veri yok
Marcin Mankowski	Chief Medical Officer	less than a year	Veri yok	Veri yok
Simon Holden	Company Secretary	3.4yrs	Veri yok	Veri yok

3.4yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: OMY 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Richard Marsden	CEO, MD & Executive Director	20yrs	UK£328.00k	0.49% € 49.4k
Stephen Holgate	Co-Founder	21yrs	UK£40.00k	0.45% € 45.2k
Joseph Colliver	CFO & Executive Director	less than a year	UK£197.41k	Veri yok
Phillip Monk	Chairman of Scientific Advisory Board	14.8yrs	UK£241.00k	0.21% € 21.0k
Donna Davies	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Ratko Djukanovic	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Simon James Shaw	Non-Executive Chairman	21yrs	UK£84.00k	0.76% € 75.9k
David Campbell	Non-Executive Director & Member of Scientific Advisory Board	18.2yrs	UK£40.00k	0.16% € 16.4k
Felicity Gabbay	Member of Scientific Advisory Board & Independent Non-Executive Director	1.8yrs	UK£45.00k	Veri yok
Amanda Radford	Independent Non-Executive Director	1.6yrs	UK£45.00k	Veri yok

16.5yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: OMY 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 16.5 yıldır).

Synairgen Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Synairgen plc, Annual General Meeting, Oct 10, 2024

Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024

Less than half of directors are independent

Less than half of directors are independent

Synairgen plc Announces Executive Changes

Synairgen plc Announces Board Changes

Recent updates

Synairgen plc, Annual General Meeting, Oct 10, 2024

Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024

New minor risk - Financial data availability

Less than half of directors are independent

Less than half of directors are independent

Synairgen plc Announces Executive Changes

Synairgen plc Announces Board Changes

Synairgen plc Announces Appointment of Dr. Marcin Mankowski as Chief Medical Officer

Less than half of directors are independent

Less than half of directors are independent

Synairgen plc, Annual General Meeting, Jun 29, 2023

Less than half of directors are independent

Synairgen plc Announces the Online Publication of Data from Its Phase 3 Sprinter Trial in the Peer Reviewed European Respiratory Journal Open Research

Synairgen plc Appoints Amanda Radford FCA to the Board as an Independent Non-Executive Director and Chair of the Audit Committee

Synairgen plc Announces Topline Data for Participants Treated with Sng001 in the Us National Institutes of Health (Nih)/ Aids Clinical Trials Group (Actg)-Led Activ-2 Phase 2 Adaptive Platform Trial for Covid-19

Synairgen plc Announces Changes to Its Board

Synairgen plc to Present 60 and 90-Day Long COVID Data from Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022

Synairgen Announces Positive Findings from Analysis of Lung Samples from the SG015 Trial of SNG001 in Virally Infected COPD Patients

Synairgen plc Announces Collaboration on Universal Trial

Synairgen plc, Annual General Meeting, Jun 30, 2022

Synairgen Presents Detailed Analysis of Phase 3 Sprinter Trial Evaluating Sng001 in Hospitalised Covid-19 Patients At ATS 2022

Less than half of directors are independent

Synairgen plc to Report Fiscal Year 2021 Results on May 25, 2022

Less than half of directors are independent

Synairgen plc Provides Update on SNG001 in the ACTIV-2 Phase 3 Trial for COVID-19 and on SNG001 Activity Against Delta and Omicron Variants

Less than half of directors are independent

Synairgen plc Announces Topline Results from Phase 3 SPRINTER trial of SNG001

Less than half of directors are independent

Synairgen plc Presents In Vitro Potency Data for Interferon Beta Against SARS-CoV-2 Variants and Lung Antiviral Biomarker Data for Inhaled SNG001 at the 8th ESWI Influenza Conference

Less than half of directors are independent

No independent directors

Synairgen plc Announces Results of in Vitro Studies

Synairgen Announces Data from Home Cohort of SG016 Phase II Trial of Inhaled Interferon Beta in COVID-19 Patients and Encouraging Combined Data for Whole SG016 Trial

Synairgen Announces Dosing Has Commenced with Its Inhaled Interferon Beta Product in US Government-Funded NIH ACTIV-2 Trial in COVID-19 Outpatients

New 90-day high: €2.14

New 90-day high: €2.08

Synairgen Announces Inclusion of Its Inhaled Interferon Beta Treatment in US NIH ACTIV-2 trial in COVID-19 outpatients

Synairgen plc Announces Completion of Recruitment into Its Phase Ii Home-Based Covid-19 Study of Inhaled Interferon Beta

Synairgen Announces Commencement of Dosing in Its International Phase III Study of Inhaled Interferon Beta in Hospitalised COVID-19 Patients

Synairgen plc Provides COVID-19 Clinical Programme Update

Clinigen Group plc Signs Managed Access Program Agreement with Synairgen plc

New 90-day high - €2.52

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş